Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Targeting of Fumarate Hydratase from Mycobacterium tuberculosis Using Allosteric Inhibitors with a Dimeric-Binding Mode.

Whitehouse AJ, Libardo MDJ, Kasbekar M, Brear PD, Fischer G, Thomas CJ, Barry CE 3rd, Boshoff HIM, Coyne AG, Abell C.

J Med Chem. 2019 Sep 27. doi: 10.1021/acs.jmedchem.9b01203. [Epub ahead of print]

PMID:
31517489
2.

Design, synthesis, in silico and in vitro evaluation of novel diphenyl ether derivatives as potential antitubercular agents.

Tiwari AP, Sridhar B, Boshoff HI, Arora K, Gautham Shenoy G, Vandana KE, Varadaraj Bhat G.

Mol Divers. 2019 Sep 10. doi: 10.1007/s11030-019-09990-z. [Epub ahead of print]

PMID:
31506871
3.

Mode-of-action profiling reveals glutamine synthetase as a collateral metabolic vulnerability of M. tuberculosis to bedaquiline.

Wang Z, Soni V, Marriner G, Kaneko T, Boshoff HIM, Barry CE 3rd, Rhee KY.

Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19646-19651. doi: 10.1073/pnas.1907946116. Epub 2019 Sep 9.

PMID:
31501323
4.

C4-Phenylthio β-lactams: Effect of the chirality of the β-lactam ring on antimicrobial activity.

Kuskovsky R, Lloyd D, Arora K, Plotkin BJ, Green JM, Boshoff HI, Barry C 3rd, Deschamps J, Konaklieva MI.

Bioorg Med Chem. 2019 Oct 15;27(20):115050. doi: 10.1016/j.bmc.2019.115050. Epub 2019 Aug 20.

PMID:
31474471
5.

Inhibition of CorA-Dependent Magnesium Homeostasis Is Cidal in Mycobacterium tuberculosis.

Park Y, Ahn YM, Jonnala S, Oh S, Fisher JM, Goodwin MB, Ioerger TR, Via LE, Bayliss T, Green SR, Ray PC, Wyatt PG, Barry CE 3rd, Boshoff HI.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e01006-19. doi: 10.1128/AAC.01006-19. Print 2019 Oct.

PMID:
31383669
6.

Development of Inhibitors against Mycobacterium abscessus tRNA (m1G37) Methyltransferase (TrmD) Using Fragment-Based Approaches.

Whitehouse AJ, Thomas SE, Brown KP, Fanourakis A, Chan DS, Libardo MDJ, Mendes V, Boshoff HIM, Floto RA, Abell C, Blundell TL, Coyne AG.

J Med Chem. 2019 Aug 8;62(15):7210-7232. doi: 10.1021/acs.jmedchem.9b00809. Epub 2019 Jul 19.

7.

Investigation of ( S)-(-)-Acidomycin: A Selective Antimycobacterial Natural Product That Inhibits Biotin Synthase.

Bockman MR, Engelhart CA, Cramer JD, Howe MD, Mishra NK, Zimmerman M, Larson P, Alvarez-Cabrera N, Park SW, Boshoff HIM, Bean JM, Young VG Jr, Ferguson DM, Dartois V, Jarrett JT, Schnappinger D, Aldrich CC.

ACS Infect Dis. 2019 Apr 12;5(4):598-617. doi: 10.1021/acsinfecdis.8b00345. Epub 2019 Feb 4.

PMID:
30652474
8.

Structures of DPAGT1 Explain Glycosylation Disease Mechanisms and Advance TB Antibiotic Design.

Dong YY, Wang H, Pike ACW, Cochrane SA, Hamedzadeh S, Wyszyński FJ, Bushell SR, Royer SF, Widdick DA, Sajid A, Boshoff HI, Park Y, Lucas R, Liu WM, Lee SS, Machida T, Minall L, Mehmood S, Belaya K, Liu WW, Chu A, Shrestha L, Mukhopadhyay SMM, Strain-Damerell C, Chalk R, Burgess-Brown NA, Bibb MJ, Barry Iii CE, Robinson CV, Beeson D, Davis BG, Carpenter EP.

Cell. 2018 Nov 1;175(4):1045-1058.e16. doi: 10.1016/j.cell.2018.10.037.

9.

Discovery and Structure-Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-d-ribose 2'-Oxidase.

Oh S, Park Y, Engelhart CA, Wallach JB, Schnappinger D, Arora K, Manikkam M, Gac B, Wang H, Murgolo N, Olsen DB, Goodwin M, Sutphin M, Weiner DM, Via LE, Boshoff HIM, Barry CE 3rd.

J Med Chem. 2018 Nov 21;61(22):9952-9965. doi: 10.1021/acs.jmedchem.8b00883. Epub 2018 Nov 5.

10.

MEPicides: α,β-Unsaturated Fosmidomycin Analogues as DXR Inhibitors against Malaria.

Wang X, Edwards RL, Ball H, Johnson C, Haymond A, Girma M, Manikkam M, Brothers RC, McKay KT, Arnett SD, Osbourn DM, Alvarez S, Boshoff HI, Meyers MJ, Couch RD, Odom John AR, Dowd CS.

J Med Chem. 2018 Oct 11;61(19):8847-8858. doi: 10.1021/acs.jmedchem.8b01026. Epub 2018 Sep 24.

11.

The present state of the tuberculosis drug development pipeline.

J Libardo MD, Boshoff HI, Barry CE 3rd.

Curr Opin Pharmacol. 2018 Oct;42:81-94. doi: 10.1016/j.coph.2018.08.001. Epub 2018 Aug 23. Review.

12.

Construction of Fluorescent Analogs to Follow the Uptake and Distribution of Cobalamin (Vitamin B12) in Bacteria, Worms, and Plants.

Lawrence AD, Nemoto-Smith E, Deery E, Baker JA, Schroeder S, Brown DG, Tullet JMA, Howard MJ, Brown IR, Smith AG, Boshoff HI, Barry CE 3rd, Warren MJ.

Cell Chem Biol. 2018 Aug 16;25(8):941-951.e6. doi: 10.1016/j.chembiol.2018.04.012. Epub 2018 May 17.

13.

Expanding Benzoxazole-Based Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor Structure-Activity As Potential Antituberculosis Agents.

Chacko S, Boshoff HIM, Singh V, Ferraris DM, Gollapalli DR, Zhang M, Lawson AP, Pepi MJ, Joachimiak A, Rizzi M, Mizrahi V, Cuny GD, Hedstrom L.

J Med Chem. 2018 Jun 14;61(11):4739-4756. doi: 10.1021/acs.jmedchem.7b01839. Epub 2018 May 30.

14.

Conformationally Constrained Cinnolinone Nucleoside Analogues as Siderophore Biosynthesis Inhibitors for Tuberculosis.

Dawadi S, Boshoff HIM, Park SW, Schnappinger D, Aldrich CC.

ACS Med Chem Lett. 2018 Mar 16;9(4):386-391. doi: 10.1021/acsmedchemlett.8b00090. eCollection 2018 Apr 12.

15.

2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structure-Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization.

Murugesan D, Ray PC, Bayliss T, Prosser GA, Harrison JR, Green K, Soares de Melo C, Feng TS, Street LJ, Chibale K, Warner DF, Mizrahi V, Epemolu O, Scullion P, Ellis L, Riley J, Shishikura Y, Ferguson L, Osuna-Cabello M, Read KD, Green SR, Lamprecht DA, Finin PM, Steyn AJC, Ioerger TR, Sacchettini J, Rhee KY, Arora K, Barry CE 3rd, Wyatt PG, Boshoff HIM.

ACS Infect Dis. 2018 Jun 8;4(6):954-969. doi: 10.1021/acsinfecdis.7b00275. Epub 2018 Mar 26.

16.

Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies.

Wilson CR, Gessner RK, Moosa A, Seldon R, Warner DF, Mizrahi V, Soares de Melo C, Simelane SB, Nchinda A, Abay E, Taylor D, Njoroge M, Brunschwig C, Lawrence N, Boshoff HIM, Barry CE 3rd, Sirgel FA, van Helden P, Harris CJ, Gordon R, Ghidelli-Disse S, Pflaumer H, Boesche M, Drewes G, Sanz O, Santos G, Rebollo-Lopez MJ, Urones B, Selenski C, Lafuente-Monasterio MJ, Axtman M, Lelièvre J, Ballell L, Mueller R, Street LJ, Ghorpade SR, Chibale K.

J Med Chem. 2017 Dec 28;60(24):10118-10134. doi: 10.1021/acs.jmedchem.7b01347. Epub 2017 Dec 7.

17.

Correction for Arora et al., "Respiratory Flexibility in Response to Inhibition of Cytochrome c Oxidase in Mycobacterium tuberculosis".

Arora K, Ochoa-Montaño B, Tsang PS, Blundell TL, Dawes SS, Mizrahi V, Bayliss T, Mackenzie CJ, Cleghorn LAT, Ray PC, Wyatt PG, Uh E, Lee J, Barry CE 3rd, Boshoff HI.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01429-17. doi: 10.1128/AAC.01429-17. Print 2017 Sep. No abstract available.

18.

Design, synthesis, and evaluation of substituted nicotinamide adenine dinucleotide (NAD+) synthetase inhibitors as potential antitubercular agents.

Wang X, Ahn YM, Lentscher AG, Lister JS, Brothers RC, Kneen MM, Gerratana B, Boshoff HI, Dowd CS.

Bioorg Med Chem Lett. 2017 Sep 15;27(18):4426-4430. doi: 10.1016/j.bmcl.2017.08.012. Epub 2017 Aug 8.

19.

Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of Mycobacterium tuberculosis Dihydrofolate Reductase.

Santa Maria JP Jr, Park Y, Yang L, Murgolo N, Altman MD, Zuck P, Adam G, Chamberlin C, Saradjian P, Dandliker P, Boshoff HIM, Barry CE 3rd, Garlisi C, Olsen DB, Young K, Glick M, Nickbarg E, Kutchukian PS.

ACS Chem Biol. 2017 Sep 15;12(9):2448-2456. doi: 10.1021/acschembio.7b00468. Epub 2017 Aug 29.

20.

Susceptibility of Mycobacterium tuberculosis Cytochrome bd Oxidase Mutants to Compounds Targeting the Terminal Respiratory Oxidase, Cytochrome c.

Moosa A, Lamprecht DA, Arora K, Barry CE 3rd, Boshoff HIM, Ioerger TR, Steyn AJC, Mizrahi V, Warner DF.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01338-17. doi: 10.1128/AAC.01338-17. Print 2017 Oct.

21.

Preparation and Evaluation of Potent Pentafluorosulfanyl-Substituted Anti-Tuberculosis Compounds.

Moraski GC, Bristol R, Seeger N, Boshoff HI, Tsang PS, Miller MJ.

ChemMedChem. 2017 Jul 20;12(14):1108-1115. doi: 10.1002/cmdc.201700170. Epub 2017 Jun 27.

22.

Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays.

Nikiforov PO, Blaszczyk M, Surade S, Boshoff HI, Sajid A, Delorme V, Deboosere N, Brodin P, Baulard AR, Barry CE 3rd, Blundell TL, Abell C.

ACS Chem Biol. 2017 May 19;12(5):1390-1396. doi: 10.1021/acschembio.7b00091. Epub 2017 Apr 5.

23.

Elevation of Fumarate Levels Compromise Redox Control and Viability in Mycobacterium tuberculosis.

Ahn YM, Boshoff HI.

Cell Chem Biol. 2017 Mar 16;24(3):243-245. doi: 10.1016/j.chembiol.2017.03.003.

24.

Structure-Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions.

Liu J, Bruhn DF, Lee RB, Zheng Z, Janusic T, Scherbakov D, Scherman MS, Boshoff HI, Das S, Rakesh, Waidyarachchi SL, Brewer TA, Gracia B, Yang L, Bollinger J, Robertson GT, Meibohm B, Lenaerts AJ, Ainsa J, Böttger EC, Lee RE.

ACS Infect Dis. 2017 Jan 13;3(1):72-88. doi: 10.1021/acsinfecdis.6b00158. Epub 2016 Nov 11.

25.

Caught between two proteins: a mycobacterial inhibitor challenges the mold.

Boshoff HI.

Mol Microbiol. 2017 Jan;103(1):2-6. doi: 10.1111/mmi.13570. Epub 2016 Dec 12.

26.

Pharmacological Inhibition of Host Heme Oxygenase-1 Suppresses Mycobacterium tuberculosis Infection In Vivo by a Mechanism Dependent on T Lymphocytes.

Costa DL, Namasivayam S, Amaral EP, Arora K, Chao A, Mittereder LR, Maiga M, Boshoff HI, Barry CE 3rd, Goulding CW, Andrade BB, Sher A.

MBio. 2016 Oct 25;7(5). pii: e01675-16. doi: 10.1128/mBio.01675-16.

27.

Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis.

Park Y, Pacitto A, Bayliss T, Cleghorn LA, Wang Z, Hartman T, Arora K, Ioerger TR, Sacchettini J, Rizzi M, Donini S, Blundell TL, Ascher DB, Rhee K, Breda A, Zhou N, Dartois V, Jonnala SR, Via LE, Mizrahi V, Epemolu O, Stojanovski L, Simeons F, Osuna-Cabello M, Ellis L, MacKenzie CJ, Smith AR, Davis SH, Murugesan D, Buchanan KI, Turner PA, Huggett M, Zuccotto F, Rebollo-Lopez MJ, Lafuente-Monasterio MJ, Sanz O, Diaz GS, Lelièvre J, Ballell L, Selenski C, Axtman M, Ghidelli-Disse S, Pflaumer H, Bösche M, Drewes G, Freiberg GM, Kurnick MD, Srikumaran M, Kempf DJ, Green SR, Ray PC, Read K, Wyatt P, Barry CE 3rd, Boshoff HI.

ACS Infect Dis. 2017 Jan 13;3(1):18-33. doi: 10.1021/acsinfecdis.6b00103. Epub 2016 Oct 17.

28.

Validation of CoaBC as a Bactericidal Target in the Coenzyme A Pathway of Mycobacterium tuberculosis.

Evans JC, Trujillo C, Wang Z, Eoh H, Ehrt S, Schnappinger D, Boshoff HI, Rhee KY, Barry CE 3rd, Mizrahi V.

ACS Infect Dis. 2016 Dec 9;2(12):958-968. Epub 2016 Oct 5.

29.

Structure-Activity Relationships of the MEPicides: N-Acyl and O-Linked Analogs of FR900098 as Inhibitors of Dxr from Mycobacterium tuberculosis and Yersinia pestis.

San Jose G, Jackson ER, Haymond A, Johny C, Edwards RL, Wang X, Brothers RC, Edelstein EK, Odom AR, Boshoff HI, Couch RD, Dowd CS.

ACS Infect Dis. 2016 Dec 9;2(12):923-935. Epub 2016 Oct 12.

30.

Arrival of Imidazo[2,1-b]thiazole-5-carboxamides: Potent Anti-tuberculosis Agents That Target QcrB.

Moraski GC, Seeger N, Miller PA, Oliver AG, Boshoff HI, Cho S, Mulugeta S, Anderson JR, Franzblau SG, Miller MJ.

ACS Infect Dis. 2016 Jun 10;2(6):393-8. doi: 10.1021/acsinfecdis.5b00154. Epub 2016 Apr 12.

PMID:
27627627
31.

Bioluminescent Reporters for Rapid Mechanism of Action Assessment in Tuberculosis Drug Discovery.

Naran K, Moosa A, Barry CE 3rd, Boshoff HI, Mizrahi V, Warner DF.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6748-6757. doi: 10.1128/AAC.01178-16. Print 2016 Nov.

32.

Selective small molecule inhibitor of the Mycobacterium tuberculosis fumarate hydratase reveals an allosteric regulatory site.

Kasbekar M, Fischer G, Mott BT, Yasgar A, Hyvönen M, Boshoff HI, Abell C, Barry CE 3rd, Thomas CJ.

Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7503-8. doi: 10.1073/pnas.1600630113. Epub 2016 Jun 20.

33.

2-Aryl-8-aza-3-deazaadenosine analogues of 5'-O-[N-(salicyl)sulfamoyl]adenosine: Nucleoside antibiotics that block siderophore biosynthesis in Mycobacterium tuberculosis.

Krajczyk A, Zeidler J, Januszczyk P, Dawadi S, Boshoff HI, Barry CE 3rd, Ostrowski T, Aldrich CC.

Bioorg Med Chem. 2016 Jul 15;24(14):3133-43. doi: 10.1016/j.bmc.2016.05.037. Epub 2016 May 20.

34.

Uncovering the Serine Hydrolytic Landscape of Mycobacterium tuberculosis.

Boshoff HI.

Cell Chem Biol. 2016 Feb 18;23(2):209-211. doi: 10.1016/j.chembiol.2016.02.002.

35.

SAR and identification of 2-(quinolin-4-yloxy)acetamides as Mycobacterium tuberculosis cytochrome bc1 inhibitors.

Phummarin N, Boshoff HI, Tsang PS, Dalton J, Wiles S, Barry Rd CE, Copp BR.

Medchemcomm. 2016 Nov 1;7(11):2122-2127. doi: 10.1039/c6md00236f. Epub 2016 Aug 22.

36.

Aminopyrazolo[1,5-a]pyrimidines as potential inhibitors of Mycobacterium tuberculosis: Structure activity relationships and ADME characterization.

Soares de Melo C, Feng TS, van der Westhuyzen R, Gessner RK, Street LJ, Morgans GL, Warner DF, Moosa A, Naran K, Lawrence N, Boshoff HI, Barry CE 3rd, Harris CJ, Gordon R, Chibale K.

Bioorg Med Chem. 2015 Nov 15;23(22):7240-50. doi: 10.1016/j.bmc.2015.10.021. Epub 2015 Oct 22. Erratum in: Bioorg Med Chem. 2016 Jan 15;24(2):314. Candice, Soares de Melo [corrected to Soares de Melo, Candice].

PMID:
26522089
37.

Mycobacterium tuberculosis IMPDH in Complexes with Substrates, Products and Antitubercular Compounds.

Makowska-Grzyska M, Kim Y, Gorla SK, Wei Y, Mandapati K, Zhang M, Maltseva N, Modi G, Boshoff HI, Gu M, Aldrich C, Cuny GD, Hedstrom L, Joachimiak A.

PLoS One. 2015 Oct 6;10(10):e0138976. doi: 10.1371/journal.pone.0138976. eCollection 2015.

38.

Dynamic exometabolome analysis reveals active metabolic pathways in non-replicating mycobacteria.

Zimmermann M, Kuehne A, Boshoff HI, Barry CE 3rd, Zamboni N, Sauer U.

Environ Microbiol. 2015 Nov;17(11):4802-15. doi: 10.1111/1462-2920.13056. Epub 2015 Oct 14.

PMID:
26373870
39.

Synthesis and Pharmacokinetic Evaluation of Siderophore Biosynthesis Inhibitors for Mycobacterium tuberculosis.

Nelson KM, Viswanathan K, Dawadi S, Duckworth BP, Boshoff HI, Barry CE 3rd, Aldrich CC.

J Med Chem. 2015 Jul 23;58(14):5459-75. doi: 10.1021/acs.jmedchem.5b00391. Epub 2015 Jul 9.

40.

Putting Tuberculosis (TB) To Rest: Transformation of the Sleep Aid, Ambien, and "Anagrams" Generated Potent Antituberculosis Agents.

Moraski GC, Miller PA, Bailey MA, Ollinger J, Parish T, Boshoff HI, Cho S, Anderson JR, Mulugeta S, Franzblau SG, Miller MJ.

ACS Infect Dis. 2015 Feb 13;1(2):85-90. Epub 2014 Dec 27.

41.

Investigation and conformational analysis of fluorinated nucleoside antibiotics targeting siderophore biosynthesis.

Dawadi S, Viswanathan K, Boshoff HI, Barry CE 3rd, Aldrich CC.

J Org Chem. 2015 May 15;80(10):4835-50. doi: 10.1021/acs.joc.5b00550. Epub 2015 Apr 30.

42.

Novel 1,4-substituted-1,2,3-triazoles as antitubercular agents.

Altimari JM, Hockey SC, Boshoff HI, Sajid A, Henderson LC.

ChemMedChem. 2015 May;10(5):787-91. doi: 10.1002/cmdc.201500051. Epub 2015 Mar 18.

PMID:
25788466
43.

Non-transpeptidase binding arylthioether β-lactams active against Mycobacterium tuberculosis and Moraxella catarrhalis.

Beck TN, Lloyd D, Kuskovsky R, Minah J, Arora K, Plotkin BJ, Green JM, Boshoff HI, Barry C 3rd, Deschamps J, Konaklieva MI.

Bioorg Med Chem. 2015 Feb 1;23(3):632-47. doi: 10.1016/j.bmc.2014.11.025. Epub 2014 Dec 12.

44.

Respiratory flexibility in response to inhibition of cytochrome C oxidase in Mycobacterium tuberculosis.

Arora K, Ochoa-Montaño B, Tsang PS, Blundell TL, Dawes SS, Mizrahi V, Bayliss T, Mackenzie CJ, Cleghorn LA, Ray PC, Wyatt PG, Uh E, Lee J, Barry CE 3rd, Boshoff HI.

Antimicrob Agents Chemother. 2014 Nov;58(11):6962-5. doi: 10.1128/AAC.03486-14. Epub 2014 Aug 25. Erratum in: Antimicrob Agents Chemother. 2017 Aug 24;61(9):.

45.

Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis.

Lakshminarayana SB, Boshoff HI, Cherian J, Ravindran S, Goh A, Jiricek J, Nanjundappa M, Nayyar A, Gurumurthy M, Singh R, Dick T, Blasco F, Barry CE 3rd, Ho PC, Manjunatha UH.

PLoS One. 2014 Aug 20;9(8):e105222. doi: 10.1371/journal.pone.0105222. eCollection 2014.

46.

The three Mycobacterium tuberculosis antigen 85 isoforms have unique substrates and activities determined by non-active site regions.

Backus KM, Dolan MA, Barry CS, Joe M, McPhie P, Boshoff HI, Lowary TL, Davis BG, Barry CE 3rd.

J Biol Chem. 2014 Sep 5;289(36):25041-53. doi: 10.1074/jbc.M114.581579. Epub 2014 Jul 14.

47.

Some Nigerian anti-tuberculosis ethnomedicines: a preliminary efficacy assessment.

Ibekwe NN, Nvau JB, Oladosu PO, Usman AM, Ibrahim K, Boshoff HI, Dowd CS, Orisadipe AT, Aiyelaagbe O, Adesomoju AA, Barry CE 3rd, Okogun JI; collaboration with 73 Visited Herbalists.

J Ethnopharmacol. 2014 Aug 8;155(1):524-32. doi: 10.1016/j.jep.2014.05.059. Epub 2014 Jun 6.

48.

Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux.

Lee RE, Hurdle JG, Liu J, Bruhn DF, Matt T, Scherman MS, Vaddady PK, Zheng Z, Qi J, Akbergenov R, Das S, Madhura DB, Rathi C, Trivedi A, Villellas C, Lee RB, Rakesh, Waidyarachchi SL, Sun D, McNeil MR, Ainsa JA, Boshoff HI, Gonzalez-Juarrero M, Meibohm B, Böttger EC, Lenaerts AJ.

Nat Med. 2014 Feb;20(2):152-158. doi: 10.1038/nm.3458. Epub 2014 Jan 26.

49.

Fitness costs of rifampicin resistance in Mycobacterium tuberculosis are amplified under conditions of nutrient starvation and compensated by mutation in the β' subunit of RNA polymerase.

Song T, Park Y, Shamputa IC, Seo S, Lee SY, Jeon HS, Choi H, Lee M, Glynne RJ, Barnes SW, Walker JR, Batalov S, Yusim K, Feng S, Tung CS, Theiler J, Via LE, Boshoff HI, Murakami KS, Korber B, Barry CE 3rd, Cho SN.

Mol Microbiol. 2014 Mar;91(6):1106-19. doi: 10.1111/mmi.12520. Epub 2014 Feb 26.

50.

The effect of chain length and unsaturation on Mtb Dxr inhibition and antitubercular killing activity of FR900098 analogs.

Jackson ER, San Jose G, Brothers RC, Edelstein EK, Sheldon Z, Haymond A, Johny C, Boshoff HI, Couch RD, Dowd CS.

Bioorg Med Chem Lett. 2014 Jan 15;24(2):649-53. doi: 10.1016/j.bmcl.2013.11.067. Epub 2013 Dec 4.

Supplemental Content

Loading ...
Support Center